In UM, molecular markers including BRCA1-associated protein 1 (BAP1) mutations, preferential expressed antigen in melanoma (PRAME) expression, and characteristic chromosomal abnormalities (such as monosomy 3 and 8q amplification) have emerged as robust predictors of metastatic risk and treatment response. This evidence concerns the gene BAP1 and melanoma.